These data support the use of sacituzumab plus pembrolizumab as a potential new standard of care,” said Sara Tolaney, MD.

The Y-90 resin microspheres demonstrated a 98.5% best overall objective response rate, with all patients responding to the treatment.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.

This study examined the posttreatment experiences of 7 children with brain tumor to determine whether problems with cognition, body function, and social functioning improved over time.

III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment.

Investigators examined survival outcomes and recurrence patterns by pathologic nodal status in patients with upper tract urothelial carcinoma (UTUC) receiving neoadjuvant chemotherapy.

The albumin-bilirubin (ALBI) score can independently predict prognosis in post-surgical patients with distal cholangiocarcinoma (dCCA), a form of cholangiocarcinoma (CCA), according to results ...

KRd as a potential standard-of-care regimen in this hard-to-treat population of high-risk, newly diagnosed multiple myeloma,” said Lisa B. Leypoldt, MD.

Researchers conducted a retrospective cohort study to assess the predictive value of molecular profiling on thyroid tumor behavior.

A cooperative model may at time better serve the relationship between patient and clinician.

A distinct natural killer (NK) cell subset, termed CLL_NK, is a precursor to effector NK phenotypes and serves as a critical immunologic marker in chronic lymphocytic leukemia (CLL), offering ...

“Breast cancer survivors may have a slightly lower risk of AD compared with cancer-free individuals, potentially influenced by cancer treatments, underscoring the need for further research on ...